Fig. 1
Fig. 2
Demographic, information, comorbidities, laboratory test results during admission in patients received empirical anidulafungin or no empirical antifungal therapy
| Characteristics | Variables (N = 149) | P value | |
|---|---|---|---|
| EAT group (Case) (n = 77) | NEAT group (Control) (n = 72) | ||
| Age (year) | |||
| Mean ± SD | 60.4 ± 17.5 | 61.3 ± 17.6 | |
| Range (min-max) | 20 - 85 | 22 - 90 | 0.762 |
| Gender | |||
| Male | 41 | 40 | |
| Female | 36 | 32 | 0.870 |
| Comorbidities | |||
| Diabetes, n (%) | 64 (83.11) | 59 (81.94) | 0.001 |
| Hypertension, n (%) | 68 (88.31) | 57 (79.16) | 0.001 |
| CVD, n (%) | 37 (48.05) | 40 (55.55) | 0.842 |
| BA, n (%) | 23 (29.87) | 26 (36.11) | 0.577 |
| CKD, n (%) | 25 (32.46) | 26 (36.11) | 0.565 |
| COPD, n (%) | 14 (18.18) | 12 (16.66) | 0.784 |
| CLD, n (%) | 11 (14.28) | 8 (11.11) | 0.685 |
| PUD, n (%) | 9 (11.68) | 11 (15.27) | 0.723 |
| Arthritis, n (%) | 4 (5.19) | 3 (4.16) | 0.067 |
| PD, n (%) | 6 (7.79) | 4 (5.55) | 0.023 |
| C-reactive protein (<10.0 mg/mL) | |||
| Mean ± SD | 210.2 ± 112.5 | 221.9 ± 105 | |
| Range (min-max) | 11.7 - 390.4 | 30.4 – 388.4 | 0.515 |
| Procalcitonin (<0.1 ng/mL) | |||
| Mean ± SD | 8 ± 25.9 | 10.8 ± 27.2 | |
| Range (min-max) | 0.02 - 114 | 0.08 - 129 | 0.522 |
| White blood cell (4-11 K/μL) | |||
| Mean ± SD | 18.3 ± 4.7 | 18.1 ± 4.9 | 0.998 |
| Range (min-max) | 12.4 - 32.6 | 11.5 – 30.2 | |
| Serum creatinine (0.8-1.4 mg/dL) | |||
| Mean ± SD | 1.7 ± 0.6 | 1.6 ± 0.6 | 0.900 |
| Range (min-max) | 0.6 - 3.3 | 0.7 – 2.9 | |
| SpO2 (%), Mean ± SD | 92 ± 2 | 91 ± 3 | 0.586 |
| Range (min-max) | 86 - 96 | 87 - 98 | |
| RSO, Mean ± SD | 7 ± 6 | 7 ± 5 | 0.644 |
| Range (min-max) | 2 - 14 | 2 - 15 | |
| Respiratory rate, (breaths/min), Mean ± SD | 24 ± 3 | 25 ± 5 | 0.144 |
| Range (min-max) | 19 - 31 | 17 - 29 | |
| Heart rate (beat/min), Mean ± SD | 98 ± 14 | 98 ± 9 | 0.062 |
| Range (min-max) | 72 - 112 | 72 - 109 | |
| LDH ((U/L), Mean ± SD | 432 ± 189.4 | 467 ± 167.1 | |
| Range (min-max) | 389.4 – 526.7 | 376.3 – 632.4 | 0.048 |
| ALT (U/L), Mean ± SD | 67 ± 36.6 | 73 ± 41.2 | 0.058 |
| Range (min-max) | 59.8 – 88.3 | 56.2 – 92.6 | |
| AST (U/L), Mean ± SD | 39 ± 16.7 | 36 ± 19.3 | 0.264 |
| Range (min-max) | 32.4 – 59.7 | 33.7 – 72.3 | |
| APACHE II Score (0-30) | |||
| Mean ± SD | 18.7 ± 4.4 | 17.2 ± 4.4 | 0.005 |
| Range (min-max) | 10 - 24 | 10 - 30 | |
Incidences of invasive candidiasis and mortality rate in patients
| Group | IC* occurred during hospital-stay (%) | P value | 30-day mortality rate (n) | P value | ||
|---|---|---|---|---|---|---|
| 4 (5.19%) | ||||||
| EAT group (n = 77) | Candida pneumonia 3 (3.8) | Candida UTI 1 (1.2) | 10.39 % (8) | |||
| 1 (CA*); 2 (NAC) | 1 (NAC*) | |||||
| <0.001 | 0.040 | |||||
| 21 (29.17%) | ||||||
| NEAT group (n = 72) | Candida pneumonia 16 (22.2) | Candida UTI 3 (4.1) | Candidemia 2 (2.7) | 19.44 % (14) | ||
| 11 (CA); 5 (NAC) | 2 (CA); 1 (NAC) | 1 (CA); 1 (NAC) | ||||